Concord Medical (CCM) Services announced that the National Medical Products Administration of the People’s Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment made by the company’s equipment supplier on December 6, 2024. As previously disclosed in the Company’s annual report for the fiscal year ended December 31, 2023, Guangzhou Concord Cancer Center, a PRC subsidiary of the company offering comprehensive cancer care services, has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently obtained the large medical equipment procurement license for its proton equipment in September 2024. Upon obtaining the approval for the Registration Certificate, Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio